Shariaportfolio Inc. Has $3.27 Million Stock Position in Johnson & Johnson $JNJ

Shariaportfolio Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ) by 47.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,617 shares of the company’s stock after purchasing an additional 5,709 shares during the period. Johnson & Johnson comprises approximately 1.2% of Shariaportfolio Inc.’s investment portfolio, making the stock its 14th biggest holding. Shariaportfolio Inc.’s holdings in Johnson & Johnson were worth $3,266,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in JNJ. Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after buying an additional 3,085,180 shares during the last quarter. Geode Capital Management LLC raised its holdings in Johnson & Johnson by 2.1% during the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock worth $9,227,988,000 after acquiring an additional 1,225,676 shares in the last quarter. Norges Bank bought a new position in Johnson & Johnson in the second quarter valued at approximately $4,877,174,000. Bank of New York Mellon Corp increased its position in shares of Johnson & Johnson by 3.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock worth $4,568,313,000 after purchasing an additional 835,146 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Johnson & Johnson by 0.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock worth $2,894,979,000 after purchasing an additional 52,074 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.5%

Johnson & Johnson stock opened at $244.54 on Friday. The firm has a market cap of $589.17 billion, a price-to-earnings ratio of 22.13, a PEG ratio of 2.34 and a beta of 0.35. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $246.35. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a 50 day moving average price of $216.42 and a two-hundred day moving average price of $195.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 47.06%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on JNJ shares. Argus raised their target price on shares of Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Sunday, January 25th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $250.00 target price on shares of Johnson & Johnson in a report on Thursday, January 22nd. Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Finally, BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $233.73.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.